Log in

Relevant bibliographies by topics / Recombinant interferon / Journal articles

To see the other types of publications on this topic, follow the link: Recombinant interferon.

Journal articles on the topic 'Recombinant interferon'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Recombinant interferon.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yaar, M., A. V. Palleroni, and B. A. Gilchrest. "Normal human epidermis contains an interferon-like protein." Journal of Cell Biology 103, no. 4 (1986): 1349–54. http://dx.doi.org/10.1083/jcb.103.4.1349.

Full text

Abstract:

Interferons have been postulated to participate in growth regulation of normal body tissues and are known to inhibit growth of human epidermal keratinocytes in vitro. Polyclonal antibodies to recombinant human interferon-alpha, purified by passage over an affinity column (Sepharose coupled to the recombinant interferon), used in the indirect immunofluorescent method specifically stained the proliferative (basal) compartment of human epidermis in histological cross-sections of normal skin and in cultured keratinocyte colonies. Extracts prepared from healthy nonvirally infected keratinocyte cult

APA, Harvard, Vancouver, ISO, and other styles

2

Wagstaff, Antona J., and Karen L. Goa. "Recombinant Interferon-??-1a*." BioDrugs 10, no. 6 (1998): 471–94. http://dx.doi.org/10.2165/00063030-199810060-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Weinberg, JM, JT Wolfe, S. Sood, M. Saruk, AH Rook, and EM Spiers. "Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature." Acta Dermato-Venereologica 77, no. 2 (1997): 146–48. http://dx.doi.org/10.2340/00015555577146148.

Full text

Abstract:

Interferons are cytokines produced by cells in response to stimulation by certain antigens and infectious agents. In recent years, recombinant interferons have been developed, which have antiviral, antiproliferative, and immunomodulatory functions. Several cutaneous reactions have been reported, including cutaneous ulceration at injection sites. We now report three cases of cutaneous ulceration caused by interferon beta-1b injections. In addition, we review all of the previously reported cases of cutaneous ulceration caused by recombinant interferons and discuss the different mechanisms by whi

APA, Harvard, Vancouver, ISO, and other styles

4

Kurzrock, R., M. G. Rosenblum, J. R. Quesada, S. A. Sherwin, L. M. Itri, and J. U. Gutterman. "Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients." Journal of Clinical Oncology 4, no. 11 (1986): 1677–83. http://dx.doi.org/10.1200/jco.1986.4.11.1677.

Full text

Abstract:

Combinations of interferon-alpha and interferon-gamma demonstrate synergistic antiviral and anti-proliferative activity in vitro. Therefore, we initiated a clinical study of combination interferon therapy in humans. Eighteen patients with metastatic solid tumors received daily intramuscular (IM) injections of recombinant interferon-alpha-A (IFN alfa-2a, Roferon-A; Hoffman-LaRoche, Nutley, NJ) and recombinant IFN-gamma (rIFN-gamma) for 6 weeks. The dose levels were 0.5, 1.0, 2.0, and 5.0 X 10(6) U/m2/d of each interferon. A minimum of two patients were entered sequentially at each dose level. F

APA, Harvard, Vancouver, ISO, and other styles

5

Tsygankov, Mikhail A., and Marina V. Padkina. "Influence of PDI gene overexpression on heterological proteins production in yeast Pichia pastoris." Ecological genetics 15, no. 2 (2017): 21–30. http://dx.doi.org/10.17816/ecogen15221-30.

Full text

Abstract:

Background. The yeast Pichia pastoris is used for synthesis of recombinant secretory proteins. Overexpression of assistant genes, coding proteins involved in secretion, is one of approaches to improve the production of target protein. PpPDI gene encodes P. pastoris yeast protein disulfide isomerase (Pdi). The aim of our study was to evaluate the effect of Pdi overproduction on recombinant interferons (human interferon-alfa16 and chicken interferon-gamma) production. Materials and Methods. PpPDI gene was cloned under the control of the AOX1 gene promoter in plasmid pPICZαA. Primers for AJ302014

APA, Harvard, Vancouver, ISO, and other styles

6

Pelus, L. M., O. G. Ottmann, and K. H. Nocka. "Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, -beta, and -gamma and an effect mediated by tumor necrosis factor." Journal of Immunology 140, no. 2 (1988): 479–84. http://dx.doi.org/10.4049/jimmunol.140.2.479.

Full text

Abstract:

Abstract The effects of prostaglandin E (PGE) and recombinant human interferon-alpha, -beta, and -gamma alone and in combination were tested for their effects on the proliferation of human bone marrow granulocyte-macrophage colony-forming units (GM-CFU). When tested alone, both classes of cytokines inhibited GM-CFU proliferation. In combination, PGE and all three types of recombinant interferons synergized in their ability to inhibit GM-CFU proliferation. Progressive enrichment for marrow GM-CFU indicated that the synergistic effects of PGE and interferon were dependent upon the presence of ma

APA, Harvard, Vancouver, ISO, and other styles

7

Miller, BA, SP Perrine, G. Antognetti, et al. "Gamma-interferon alters globin gene expression in neonatal and adult erythroid cells." Blood 69, no. 6 (1987): 1674–81. http://dx.doi.org/10.1182/blood.v69.6.1674.1674.

Full text

Abstract:

Abstract Interferons have the ability to enhance or diminish the expression of specific genes and have been shown to affect the proliferation of certain cells. Here, the effect of gamma-interferon on fetal hemoglobin synthesis by purified cord blood, fetal liver, and adult bone marrow erythroid progenitors was studied with a radioligand assay to measure hemoglobin production by BFU-E-derived erythroblasts. Coculture with recombinant gamma-interferon resulted in a significant and dose- dependent decrease in fetal hemoglobin production by neonatal and adult, but not fetal, BFU-E-derived erythrob

APA, Harvard, Vancouver, ISO, and other styles

8

Miller, BA, SP Perrine, G. Antognetti, et al. "Gamma-interferon alters globin gene expression in neonatal and adult erythroid cells." Blood 69, no. 6 (1987): 1674–81. http://dx.doi.org/10.1182/blood.v69.6.1674.bloodjournal6961674.

Full text

Abstract:

Interferons have the ability to enhance or diminish the expression of specific genes and have been shown to affect the proliferation of certain cells. Here, the effect of gamma-interferon on fetal hemoglobin synthesis by purified cord blood, fetal liver, and adult bone marrow erythroid progenitors was studied with a radioligand assay to measure hemoglobin production by BFU-E-derived erythroblasts. Coculture with recombinant gamma-interferon resulted in a significant and dose- dependent decrease in fetal hemoglobin production by neonatal and adult, but not fetal, BFU-E-derived erythroblasts. Ac

APA, Harvard, Vancouver, ISO, and other styles

9

Lokshina, E. E., V. V. Malinovskaya, O. V. Zaytseva, and S. U. Snitko. "Virus-induced asthma: how to achieve good disease control?" Voprosy praktičeskoj pediatrii 15, no. 6 (2020): 52–66. http://dx.doi.org/10.20953/1817-7646-2020-6-52-66.

Full text

Abstract:

This article discusses the role of various respiratory viruses in the development of bronchial asthma and in triggering its exacerbation. It covers the pathogenetic mechanisms underlying virus-induced bronchial asthma and the importance of interferons for disease control. We summarized the results of international and Russian studies analyzing the utility of type 1 interferons for children and adults with virus-induced asthma exacerbations. Combination drugs containing recombinant α2b interferon plus α-tocopheryl acetate plus ascorbic acid have demonstrated their efficacy in the prevention and

APA, Harvard, Vancouver, ISO, and other styles

10

Hamilton, A. O., L. Jones, L. Morrison, and K. Whaley. "Modulation of monocyte complement synthesis by interferons." Biochemical Journal 242, no. 3 (1987): 809–15. http://dx.doi.org/10.1042/bj2420809.

Full text

Abstract:

Recombinant Escherichia coli-derived gamma-interferon has been shown to stimulate synthesis of the second component of complement (C2), factor B and C1 inhibitor, but to inhibit synthesis of the third component (C3). alpha- and beta-interferons stimulate synthesis of factor B and C3 inhibitor, inhibit C5 synthesis but do not alter synthesis of C2. alpha- and beta-interferons act synergistically with gamma-interferon to enhance both factor B and C1-inhibitor synthesis.

APA, Harvard, Vancouver, ISO, and other styles

11

Gaiderova, L. A., Yu N. Lebedeva, T. N. Lobanova, E. K. Lipatova, R. A. Volkova та O. V. Fadeikina. "Certification of a pharmacopoeial reference standard for potency testing of recombinant interferon α-2b". Biological Products. Prevention, Diagnosis, Treatment 24, № 1 (2024): 21–31. http://dx.doi.org/10.30895/2221-996x-2024-24-1-21-31.

Full text

Abstract:

SCIENTIFIC RELEVANCE. Potency testing of recombinant interferons requires a reference standard. The availability of International Standards (ISs) that are commonly used to assess the quality of recombinant interferons is currently limited. Therefore, the quality of interferons should be assessed using pharmacopoeial reference standards (RSs) certified using ISs (if available).AIM. This study aimed to certify a pharmacopoeial RS for potency testing of recombinant interferon α-2b.MATERIALS AND METHODS. The potency determination involved comparing the inhibition of the virus-induced cytopathic ef

APA, Harvard, Vancouver, ISO, and other styles

12

Kanzaki, Hiroyuki, Mirei Chiba, Maiko Suzuki, and Martin Taubman. "TNF-alpha Converting Enzyme Degradates Interferon-Gamma. (174.15)." Journal of Immunology 188, no. 1_Supplement (2012): 174.15. http://dx.doi.org/10.4049/jimmunol.188.supp.174.15.

Full text

Abstract:

Abstract Infection induced immune responses cause extensive bone destruction in periodontitis. We previously reported that TNF-alpha converting enzyme (TACE) play a role in soluble RANKL and soluble TNF-alpha cleavage from activated lymphocytes in periodontitis, and these soluble osteoclastogenic cytokines induce osteoclast activation from distant site. Interferon-gamma is known as anti-osteoclastogenic cytokine produced from activated T cells, but little is known about the post-transcriptive modification, especially in inflamed tissue. We hypothesized that TACE might modify interferon-gamma a

APA, Harvard, Vancouver, ISO, and other styles

13

SMU, Kadir. "Recombinant Interferon-Alpha 2b for Ocular Surface Squamous Neoplasia (OSSN)." Open Access Journal of Ophthalmology 6, no. 1 (2021): 1–3. http://dx.doi.org/10.23880/oajo-16000218.

Full text

Abstract:

Ocular surface squamous neoplasia (OSSN) is an ambit of ocular surface diseases encompassing dysplasia to different grades of invasive squamous cell carcinoma of the ocular surface. The typical presentation is the leukoplakic appearance with feeder vessels of conjunctiva, limbus, and cornea. Histological confirmation after incisional/excisional biopsy has been considered the gold standard for OSSN. 5-fluorouracil (5-FU) and mitomycin C (MMC) has used as adjuvant topical chemotherapy. Recently, interferon-alpha 2b (INF α2b) is operating as immunotherapy for the treatment of OSSN. Good outcome w

APA, Harvard, Vancouver, ISO, and other styles

14

Buraglio, M., I. Trinchard-Lugan, A. Munafo, and M. Macnamee. "Recombinant Human Interferon-??-1a (Rebif??) vs Recombinant Interferon-??-1b (Betaseron??) in Healthy Volunteers." Clinical Drug Investigation 18, no. 1 (1999): 27–34. http://dx.doi.org/10.2165/00044011-199918010-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Browning, J. L., and A. Ribolini. "Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes." Journal of Immunology 138, no. 9 (1987): 2857–63. http://dx.doi.org/10.4049/jimmunol.138.9.2857.

Full text

Abstract:

Abstract We have studied the short-term effects of interleukin 1, lipopolysaccharide, and interferon on prostaglandin release from freshly isolated human peripheral monocytes. When the cells were pretreated for 8 to 9 hr with either E. coli lipopolysaccharide or recombinant interleukin 1 (beta), prostaglandin release increased. Inclusion of recombinant IFN-alpha or IFN-gamma during the pretreatment phase blocked subsequent prostaglandin release. Interferons were effective at concentrations in the range of 1 to 10 antiviral units/ml, and the inhibition was manifested within several hours after

APA, Harvard, Vancouver, ISO, and other styles

16

O'Sullivan, M. G., L. N. Fleisher, N. C. Olson, N. J. MacLachlan, and T. T. Brown. "Modulation of arachidonic acid metabolism by bovine alveolar macrophages exposed to interferons and lipopolysaccharide." American Journal of Veterinary Research 51, no. 11 (1990): 1820–25. http://dx.doi.org/10.2460/ajvr.1990.51.11.1820.

Full text

Abstract:

SUMMARY Stimulation of bovine alveolar macrophages with calcium ionophore A23187 resulted in marked production of leukotriene (lt)B4 and a lesser increase in thromboxane (tx)B2, whereas opsonized zymosan (opz) resulted in production of txb2 and relatively small increases in ltb4 and prostaglandin (pg)F2α. Alveolar macrophages incubated with recombinant bovine interferon-γ or lipopolysaccharide, and subsequently stimulated with A23187 or opz, had altered arachidonic acid metabolism, producing markedly increased amounts of txb2 and pgf2α, and slightly increased ltb4. Incubation of alveolar macro

APA, Harvard, Vancouver, ISO, and other styles

17

Murdoch, David, and Katherine A. Lyseng-Williamson. "Subcutaneous Recombinant Interferon-??-1a (Rebif??)." Drugs 65, no. 9 (2005): 1295–312. http://dx.doi.org/10.2165/00003495-200565090-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cohen, Mylan C., Marks Huberman, and Richard W. Nesto. "Recombinant alpha2 interferon-related cardiomyopathy." American Journal of Medicine 85, no. 4 (1988): 549–51. http://dx.doi.org/10.1016/s0002-9343(88)80094-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Durand, Jean Marc, Nathalie Quiles, Gilles Kaplanski та Jacques Soubeyrand. "Thrombosis and recombinant interferon-α". American Journal of Medicine 95, № 1 (1993): 115. http://dx.doi.org/10.1016/0002-9343(93)90242-h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Schulze, H. J. "Recombinant interferon gamma in psoriasis." Archives of Dermatology 124, no. 4 (1988): 487–89. http://dx.doi.org/10.1001/archderm.124.4.487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Schulze, Hans-Joachim. "Recombinant Interferon Gamma in Psoriasis." Archives of Dermatology 124, no. 4 (1988): 487. http://dx.doi.org/10.1001/archderm.1988.01670040007003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Koyama, A. Hajime, Tsutomu Arakawa та Akio Adachi. "Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-α-2b". Microbes and Infection 1, № 13 (1999): 1073–77. http://dx.doi.org/10.1016/s1286-4579(99)00210-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ernstoff, M. S., S. Nair, R. R. Bahnson, et al. "A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma." Journal of Clinical Oncology 8, no. 10 (1990): 1637–49. http://dx.doi.org/10.1200/jco.1990.8.10.1637.

Full text

Abstract:

This study investigated the effects of sequentially administered recombinant interferon gamma (rIFN gamma) and recombinant interferon alfa (rIFN alpha) in 36 patients with metastatic renal cell carcinoma (RCC). rIFN alpha was subcutaneously administered daily for 70 days at dosages that varied (2.5, 5, 10, and 20 x 10(6) U/m2) across four cohorts of patients. Within each cohort of patients receiving a given dose of rIFN alpha, three subsets of patients received either 30, 300, or 1,000 micrograms/m2 rIFN gamma. rIFN gamma was administered intravenously for 5 days every third week, 6 hours prio

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmed, Maryam, Margie O. McKenzie, Shelby Puckett, Michael Hojnacki, Laurent Poliquin, and Douglas S. Lyles. "Ability of the Matrix Protein of Vesicular Stomatitis Virus To Suppress Beta Interferon Gene Expression Is Genetically Correlated with the Inhibition of Host RNA and Protein Synthesis." Journal of Virology 77, no. 8 (2003): 4646–57. http://dx.doi.org/10.1128/jvi.77.8.4646-4657.2003.

Full text

Abstract:

ABSTRACT The vesicular stomatitis virus (VSV) matrix (M) protein plays a major role in the virus-induced inhibition of host gene expression. It has been proposed that the inhibition of host gene expression by M protein is responsible for suppressing activation of host interferon gene expression. Most wild-type (wt) strains of VSV induce little if any interferon gene expression. Interferon-inducing mutants of VSV have been isolated previously, many of which contain mutations in their M proteins. However, it was not known whether these M protein mutations were responsible for the interferon-indu

APA, Harvard, Vancouver, ISO, and other styles

25

Omara, Denis, Fortunate Natwijuka, Anne Kapaata, et al. "Subtype AD Recombinant HIV-1 Transmitted/Founder Viruses Are Less Sensitive to Type I Interferons than Subtype D." Viruses 17, no. 4 (2025): 486. https://doi.org/10.3390/v17040486.

Full text

Abstract:

Initial interactions between HIV-1 and the immune system at mucosal exposure sites play a critical role in determining whether the virus is eliminated or progresses to establish systemic infection. The virus that successfully crosses the mucosal barrier to establish infection in the new host is referred to as the transmitted/founder (TF) virus. Following mucosal HIV-1 transmission, type 1 interferons (IFN-I) are rapidly induced at sites of initial virus replication. The resistance of TF variants to these antiviral effects of the IFN-I has been studied among HIV-1 subtypes B and C. However, the

APA, Harvard, Vancouver, ISO, and other styles

26

Brown, T. D., J. Koeller, K. Beougher, et al. "A phase I clinical trial of recombinant DNA gamma interferon." Journal of Clinical Oncology 5, no. 5 (1987): 790–98. http://dx.doi.org/10.1200/jco.1987.5.5.790.

Full text

Abstract:

Recombinant gamma interferon (r-GIFN) demonstrates in vitro and in vivo characteristics that contrast with those of alpha and beta interferons. It has relatively weak antiviral properties, yet relatively potent immunomodulatory effects. A phase I trial was performed with r-GIFN (specific activity 2.6 X 10(6) IU/mg protein), administered as a continuous intravenous (IV) infusion over 24 hours for five days (Cl X 5) and repeated every 28 days. This schedule was chosen based on the short half-life of r-GIFN in animal systems and the in vitro augmentation of biologic effects with continuous exposu

APA, Harvard, Vancouver, ISO, and other styles

27

Johnson, RE, JC Johnson, SJ Kloberdanz, and MJ Morrill. "Recombinant alpha-interferon and verruca plantaris. A review of the literature." Journal of the American Podiatric Medical Association 81, no. 5 (1991): 253–57. http://dx.doi.org/10.7547/87507315-81-5-253.

Full text

Abstract:

The authors review the literature and report the mechanisms of action, chemical properties, pharmacokinetics, adverse effects, and clinical studies of recombinant alpha-interferon. The authors believe that clinical trials should be performed with recombinant alpha-interferon therapy on verruca plantaris to prove or disprove the effectiveness of interferon as a potential treatment modality for these commonly encountered lesions.

APA, Harvard, Vancouver, ISO, and other styles

28

Hagmaier, Kathrin, Stephanie Jennings, Johanna Buse, Friedemann Weber, and Georg Kochs. "Novel Gene Product of Thogoto Virus Segment 6 Codes for an Interferon Antagonist." Journal of Virology 77, no. 4 (2003): 2747–52. http://dx.doi.org/10.1128/jvi.77.4.2747-2752.2003.

Full text

Abstract:

ABSTRACT Thogoto virus (THOV) is a tick-transmitted orthomyxovirus with a genome of six negative-stranded RNA segments. The sixth segment encodes two different transcripts: a spliced transcript that is translated into the matrix protein (M) and an unspliced transcript. Here, we report that the unspliced transcript encodes an elongated form of M named ML. A THOV isolate deficient in ML expression was an efficient interferon inducer, whereas ML-expressing wild-type strains were poor interferon inducers. These results were confirmed with recombinant THOVs rescued from cDNAs. Expression of ML effi

APA, Harvard, Vancouver, ISO, and other styles

29

Brzoska, Josef, Harald von Eick, and Manfred Hündgen. "Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta." Drug Research 70, no. 07 (2020): 291–97. http://dx.doi.org/10.1055/a-1170-4395.

Full text

Abstract:

AbstractThe pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This

APA, Harvard, Vancouver, ISO, and other styles

30

Mazankova, L. N., S. G. Gorbunov, and E. R. Samitova. "The value of interferon therapy for COVID-19 in children." CHILDREN INFECTIONS 20, no. 1 (2021): 34–38. http://dx.doi.org/10.22627/2072-8107-2021-20-1-34-38.

Full text

Abstract:

The article presents a literature review, which provides data on the role of interferons in the immunopathogenesis of COVID-19 and the clinical efficacy of drugs based on recombinant interferon-alpha 2b in the treatment of children with new coronavirus infection. Shown the leading role ofinterferons as factors of the first line of defense against various viruses, including SARS-CoV-2. Numerous studies have proven the feasibility of including interferon preparations in COVID-19 therapyregimens in children, both as combinations with antiviral agents and as monotherapy.

APA, Harvard, Vancouver, ISO, and other styles

31

Muttar, A. A. "Cloning and gene expression equine leukocyte α-interferon in cells of Escherichia Coli". Al-Qadisiyah Journal of Veterinary Medicine Sciences 12, № 1 (2013): 82. http://dx.doi.org/10.29079/vol12iss1art234.

Full text

Abstract:

Interferon plays role in innate immune responses through upregulation of costimulatory molecules and induction of proinflammatory cytokines. interferons including interferon alpha (IFNA). The present study characterized IFNA cDNA and predicted protein. The interferon’s play a great role in protection from infections, which have been called by microorganisms, and also have powerful antiproliferation and immunomodulation activity. The purposes of study: cloning and expression of horse leukocyte interferon and purification the product protein. The results and discussion : In the result we isolate

APA, Harvard, Vancouver, ISO, and other styles

32

Bosch, Orencio, Gloria Moraleda, Inmaculada Castillo, and Vicente Carreño. "Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole." Journal of Hepatology 19, no. 3 (1993): 437–41. http://dx.doi.org/10.1016/s0168-8278(05)80555-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sasseville, Denis, Walid Al Ghamdi, and Sultan Al Khenaizan. "Interferon-Induced Cutaneous Necrosis." Journal of Cutaneous Medicine and Surgery 3, no. 6 (1999): 320–23. http://dx.doi.org/10.1177/120347549900300610.

Full text

Abstract:

Background: Due to advances in recombinant DNA technology, interferons are now readily available and are frequently used in all branches of medicine. These potent biologic response modifiers carry a number of systemic and local side effects. These cytokines are usually administered subcutaneously, and recent studies have described the occurrence of inflammation or necrosis at the site of injection. Objective: We report a case of cutaneous necrosis at the sites of interferon injections in a 35-year-old man treated for chronic myeloid leukemia with high, daily doses of interferon alfa. In additi

APA, Harvard, Vancouver, ISO, and other styles

34

Lucivero, G. "The Interferons in Clinical Practice." International Journal of Immunopathology and Pharmacology 5, no. 2 (1992): 83–92. http://dx.doi.org/10.1177/039463209200500203.

Full text

Abstract:

In the last decade, recombinant DNA technologies have allowed the production of highly purified interferons in virtually unlimited amounts. Therefore it has become possible to evaluate the usefulness of interferon therapy in several different diseases. Nowadays interferons have a well defined role in the therapy of infectious and malignant diseases. As these natural modifiers of biological responses are widely available to the specialist and to the general practitioner as well, in the present paper we review the main biochemical properties and the molecular mechanisms underlying the heterogene

APA, Harvard, Vancouver, ISO, and other styles

35

Jacobs, AD, RE Champlin, and DW Golde. "Recombinant alpha-2-interferon for hairy cell leukemia." Blood 65, no. 4 (1985): 1017–20. http://dx.doi.org/10.1182/blood.v65.4.1017.1017.

Full text

Abstract:

Abstract Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) alpha-2-interferon in an open-label, single- arm efficacy study. Patients received 2 X 10(6) U/m2 recombinant alpha- 2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of

APA, Harvard, Vancouver, ISO, and other styles

36

Jacobs, AD, RE Champlin, and DW Golde. "Recombinant alpha-2-interferon for hairy cell leukemia." Blood 65, no. 4 (1985): 1017–20. http://dx.doi.org/10.1182/blood.v65.4.1017.bloodjournal6541017.

Full text

Abstract:

Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) alpha-2-interferon in an open-label, single- arm efficacy study. Patients received 2 X 10(6) U/m2 recombinant alpha- 2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of therapy w

APA, Harvard, Vancouver, ISO, and other styles

37

Zhang, Hui, Jianchun Xian, Yang Li, Li Xiao та Lu Wang. "Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis". Evidence-Based Complementary and Alternative Medicine 2022 (30 червня 2022): 1–8. http://dx.doi.org/10.1155/2022/1889628.

Full text

Abstract:

Objective. To systematically evaluate the clinical value of tenofovir combined with recombinant human interferon α-2b in the treatment of chronic hepatitis B and to provide evidence-based medicine for its popularization and use. Methods. The randomized controlled trials (RCTs) of tenofovir combined with recombinant human interferon α-2b in the online database of PubMed, EMBASE, ScienceDirect, Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang database, and China Biomedical Literature Database (CBM) were searched. The data included in this study were extracted by two

APA, Harvard, Vancouver, ISO, and other styles

38

Chronopoulou, Sofia, and Ilias Tsochantaridis. "Interferon Lambda: The Next Frontier in Antiviral Therapy?" Pharmaceuticals 18, no. 6 (2025): 785. https://doi.org/10.3390/ph18060785.

Full text

Abstract:

Type III interferons (IFN-λ) are the most recently identified members of the interferon family, distantly related to type I interferons and members of the interleukin-10 (IL-10). Unlike type I interferons, which have broadly distributed cellular receptors, IFN-λ signals through a heterodimeric receptor complex with primary expression on epithelial cells. This restricted receptor distribution makes IFN-λ a favorable candidate for therapeutic and antiviral applications with reduced side effects. In this review, we describe the molecular structure, signaling mechanisms, and the role of IFN-λ in t

APA, Harvard, Vancouver, ISO, and other styles

39

Zhakov, Y. I., E. E. Minina та L. V. Medvedeva. "Тhe prophylactic efficacy of a recombinant interferon alfa-2b drug in children with bronchial asthma". CHILDREN INFECTIONS 18, № 3 (2019): 25–30. http://dx.doi.org/10.22627/2072-8107-2019-18-3-25-30.

Full text

Abstract:

A prospective cohort study was conducted to assess the effect of a recombinant interferon alpha-2b prophylactic course on cyto-immunological parameters of induced sputum in children with mild asthma, the main trigger of exacerbation of which was respiratory viral infections.We examined 40 children aged 1 to 7 years with (mean age — 4.8 ± 0.2 years), half of whom received a course of recombinant interferon alpha-2b. The authors detected respiratory viruses in scrapings from throat and nose (PCR method) and evaluated the different cell counts, also the levels of interleukin-10, tumor necrosis fa

APA, Harvard, Vancouver, ISO, and other styles

40

Shirshev, S. V. "The role of hormonal-cytokine interactions in the formation of humoral immune response." Problems of Endocrinology 41, no. 1 (1995): 32–34. http://dx.doi.org/10.14341/probl11347.

Full text

Abstract:

The functional activity of splenocytes of CBA mice was investigated in a syngeneic transfer system by the level of formation of antibody-producing cells (APC). Splenocytes were preincubated for 1 h in vitro with chorionic gonadotropin and type I recombinant interferons, as well as in hormonal-cytokine combinations. Chorionic gonadotropin in doses 10 and 50 MU/ml depressed APC formation, whereas alpha-interferon (250 MU/ml) stimulated it, and beta-interferon in the same concentration did not influence the level of humoral immune response. Chorionic gonadotropin, if added to splenocyte culture i

APA, Harvard, Vancouver, ISO, and other styles

41

Adelmann-Grill, Bernhard C., R�diger Hein, Franz Wach, and Thomas Krieg. "Inhibition of fibroblast chemotaxis by recombinant human interferon ? and interferon ?" Journal of Cellular Physiology 130, no. 2 (1987): 270–75. http://dx.doi.org/10.1002/jcp.1041300213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Cohen, Jeffrey I., and Kristen Lekstrom. "Epstein-Barr Virus BARF1 Protein Is Dispensable for B-Cell Transformation and Inhibits Alpha Interferon Secretion from Mononuclear Cells." Journal of Virology 73, no. 9 (1999): 7627–32. http://dx.doi.org/10.1128/jvi.73.9.7627-7632.1999.

Full text

Abstract:

ABSTRACT The Epstein-Barr virus (EBV) BARF1 gene encodes a soluble colony-stimulating factor 1 (CSF-1) receptor that neutralizes the effects of CSF-1 in vitro. To study the effect of BARF1 on EBV-induced transformation, we added recombinant BARF1 to B cells in the presence of EBV. BARF1 did not enhance transformation of B cells by EBV in vitro. To study the role of BARF1 in the context of EBV infection, we constructed a recombinant EBV mutant with a large deletion followed by stop codons in the BARF1 gene as well as a recombinant virus with a wild-type BARF1 gene. While BARF1 has previously be

APA, Harvard, Vancouver, ISO, and other styles

43

Corona, T., C. Leon, and L. Ostrosky-Zeichner. "Severe anaphylaxis with recombinant interferon beta." Neurology 52, no. 2 (1999): 425. http://dx.doi.org/10.1212/wnl.52.2.425-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

TANAKA, TOSHIAKI, MASANOBU NARUTO та GENJI KAWANO. "Production of Recombinant Mouse β-Interferon". Journal of Interferon Research 6, № 4 (1986): 429–35. http://dx.doi.org/10.1089/jir.1986.6.429.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Recombinant interferon alpha controls polycythaemia vera." Inpharma Weekly &NA;, no. 765 (1990): 11. http://dx.doi.org/10.2165/00128413-199007650-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Merimsky, Ofer, Menachem Rubinstein, Dina Fischer, Abraham Danon, and Samario Chaitchik. "Pharmacokinetics of recombinant interferon alpha-C." Cancer Chemotherapy and Pharmacology 27, no. 5 (1991): 406–8. http://dx.doi.org/10.1007/bf00688867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Roosth, Joe, Richard B. Pollard, S. Lori Brown та Walter J. Meyer. "Cortisol stimulation by recombinant interferon-α2". Journal of Neuroimmunology 12, № 4 (1986): 311–16. http://dx.doi.org/10.1016/0165-5728(86)90037-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gross, G. "Recombinant interferon gamma in condylomata acuminata." JAMA: The Journal of the American Medical Association 266, no. 19 (1991): 2706. http://dx.doi.org/10.1001/jama.266.19.2706.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Gross, Gerd. "Recombinant Interferon Gamma in Condylomata Acuminata." JAMA: The Journal of the American Medical Association 266, no. 19 (1991): 2706. http://dx.doi.org/10.1001/jama.1991.03470190054028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Morhenn, Vera B. "Recombinant Interferon Gamma in Psoriasis-Reply." Archives of Dermatology 124, no. 4 (1988): 488. http://dx.doi.org/10.1001/archderm.1988.01670040008004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!